# Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

> **NCT01504477** · PHASE1,PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 6 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab and bortezomib

## Key facts

- **NCT ID:** NCT01504477
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low accrual--unable to meet accrual goals
- **Last updated:** 2020-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01504477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01504477, "Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01504477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*